Active Biotech’s partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer


You May Also Like

Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference

MADISON, Wis., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused ...

Epistem management buy-out

MANCHESTER, United Kingdom, June 12, 2018 (GLOBE NEWSWIRE) -- Epistem, the Manchester UK-based Contract ...